To address this, the study hypothesized that memory-like (ML) NK cell differentiation, tumor targeting with cetuximab, and engineering with an anti-EphA2 CAR could improve NK cell responses against HNSCC. The gene discussed is EPHA2; the disease is head and neck squamous cell carcinoma.